FGF21 and metabolic disease: And during past decades, the beneficial effect of FGF21 analogs and FGF21-receptor agonists confirmed by preclinical and clinical experiments has indicated that FGF21 is an attractive target for the treatment of metabolic diseases, particularly for obesity, T2DM, and NASH.